Sumitovant subsidiaries Enzyvant and Altavant merge into combined company
Two Sumitovant Biopharma entities are merging under one name, effective immediately.
Enzyvant Therapeutics and Altavant Sciences announced they have merged to form a singular entity focused on developing therapies for patients with rare diseases. The combined company will keep the name Enzyvant and along with clinical development will eventually include in-house manufacturing.
Bill Symonds, the current CEO of both Altavant and Enzyvant, is now CEO of the merged company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.